Company Profile
CVRx Stock Price, News & Analysis
- Ticker:
- CVRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.94 USD (+6.45%)
Close
Last updated: August 6, 2026
144M USD
Market cap
Why the stock is moving
The latest monitored company update is “CVRx Reports Second Quarter 2026 Financial and Operating Results.” The corresponding closing-price reaction is not yet available.
Company overview
Cardiovascular Neuromodulation
CVRx is a commercial-stage medical-device company focused on neuromodulation therapies for cardiovascular disease. Its technology electrically activates the body's baroreflex to influence autonomic pathways involved in heart-failure progression.
Barostim Platform
Barostim is the company's implantable therapy for patients with heart failure who remain symptomatic despite guideline-directed medical management. The system is placed by trained physicians and supported through a specialized implanting-center network. CVRx is conducting BENEFIT-HF, a randomized controlled study designed to evaluate Barostim's effect on mortality and heart-failure decompensation in an expanded patient population. The trial complements the company's commercial evidence-generation strategy.
Future catalysts
CVRx’s catalysts are Barostim adoption, reimbursement, and continued growth in heart-failure and hypertension use cases. The company’s stock tends to move when utilization broadens.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of CVRx (CVRX)?
CVRx (CVRX) most recently closed at 5.94 USD, a +6.45% move versus the previous session.
What is the market cap of CVRx (CVRX)?
CVRx currently has a market capitalization of 144M USD on BioPharmSignal.
What does CVRx do?
Cardiovascular Neuromodulation CVRx is a commercial-stage medical-device company focused on neuromodulation therapies for cardiovascular disease. Its technology electrically activates the body's baroreflex to influence autonomic pathways involved in heart-failure progression. Barostim Platform Barostim is the company's implantable therapy for patients with...
On which exchange is CVRX stock listed?
CVRx (CVRX) is associated with NASDAQ, United States, Biopharma.
What is BENEFIT-HF?
CVRx is conducting BENEFIT-HF, a randomized controlled study designed to evaluate Barostim's effect on mortality and heart-failure decompensation in an expanded patient population.
Which conditions is CVRx targeting with BENEFIT-HF?
CVRx is associated with cardiovascular disease based on its company overview and current catalyst commentary.
How does CVRx describe recent progress with BENEFIT-HF?
CVRx’s catalysts are Barostim adoption, reimbursement, and continued growth in heart-failure and hypertension use cases. The company’s stock tends to move when utilization broadens.
What is Cardiovascular?
Cardiovascular Neuromodulation CVRx is a commercial-stage medical-device company focused on neuromodulation therapies for cardiovascular disease.